IP Library Granted Patent US 8,232,398
Granted Patent B2
US 8,232,398 · App. 12/586,856 · Granted Jul 31, 2012

Recycling process for increasing the yield of opiate alkaloid derivatives

Assignee: Mallinckrodt LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,232,398
App. No.
12/586,856
Granted
Jul 31, 2012
Kind
B2
Abstract

The present invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for increasing the yield of opiate alkaloids by introducing at least one recycling step.

Claims (37)

1. A process for the preparation of a compound of Formula (II), the process comprising:

(a) forming a reaction mixture that comprises a compound of Formula (I) and R 9 MgX 1 such that a reaction occurs to yield a reaction product that comprises the compound of Formula (II) and an amount of the compound of Formula (I) that is unreacted according to the following reaction scheme:

wherein:

R 1 , R 8 R 9 , and R 10 are independently selected from the group consisting of hydrocarbyl and substituted hydrocarbyl;

R 2 and R 3 are independently selected from the group consisting of hydrogen, hydrocarbyl and substituted hydrocarbyl;

R 4 and R 5 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, halogen, {—}OH, {—}NH 2 , {—}SH, {—}SR 10 , and {—}OR 10 ;

R 6 and R 7 are independently selected from the group consisting of hydrogen, a protecting group, hydrocarbyl, and substituted hydrocarbyl;

X is oxygen; and

X 1 is a halogen atom;

(b) quenching the reaction product of step (a);

(c) filtering the quenched reaction product of step (b) to form a filtrate comprising an amount of the compound of Formula (I) and an amount of the compound of Formula (II); and

(d) recycling by combining the filtrate of step (c) with the reaction mixture of step (a) and repeating steps (b) and (c).

2. The process of claim 1 , wherein R 1 , R 6 , R 7 , and R 8 are alkyl or substituted alkyl; and R 9 is selected from the group consisting of alkyl, substituted alkyl, aryl, and substituted aryl.

3. The process of claim 2 , wherein R 2 , R 3 , R 4 , and R 6 are hydrogen.

4. The process of claim 1 , wherein R 9 is an alkyl or substituted alkyl, and X 1 is chloride or bromide.

5. The process of claim 1 , wherein step (d) is repeated up to four times.

6. The process of claim 1 , wherein the molar ratio of the compound of Formula (I) to R 9 MgX 1 is from about 1:1 to about 1:5; step (a) is conducted at a temperature of from about 15° C. to about 100° C. and in the presence of a solvent system comprising an aprotic solvent; the reaction of step (b) is cooled to a temperature of less than about 20° C.; and step (d) is repeated up to four times.

7. The process of claim 6 , wherein R 9 is an alkyl or substituted alkyl; X 1 is chloride or bromide; and the solvent system comprises toluene and tetrahydrofuran.

8. The process of claim 6 , wherein an amount of the compound of Formula (II) crystallizes in step (b) as the reaction mixture is cooled.

9. The process of claim 1 , wherein repeating step (d) four times increases the yield of the compound of Formula (II) by at least 20% compared to when no recycling step (d) is performed.

10. The process of claim 1 , wherein the optical activity of the compound of Formula (I) or (II) is selected from the group consisting of (+), (−), and combinations thereof; the configuration of each of C5 and C6 is R; and the configuration of C7, C9, C13, and C14, respectively, is selected from the group consisting of RRSS, RSRR, SRSS, and SSRR, provided that the C15 and the C16 carbons are both either on the alpha face or the beta face of the molecule.

11. A process for the preparation of a compound of Formula (IIa), the process comprising:

(a) forming a reaction mixture that comprises a compound of Formula (Ia) and tertiary-butylMgX 1 such that a reaction occurs to yield a reaction product that comprises the compound of Formula (IIa) and an amount of the compound of comprising Formula (Ia) that is unreacted according to the following reaction scheme:

wherein:

X 1 is a halogen atom;

(b) quenching the reaction product of step (a);

(c) filtering the quenched reaction product of step (b) to form a filtrate comprising an amount of the compound of Formula (Ia) and an amount of the compound of Formula (IIa); and

(d) recycling by combining the filtrate of step (c) with the reaction mixture of step (a) and repeating steps (b) and (c).

12. The process of claim 11 , wherein step (d) is repeated up to four times.

13. The process of claim 11 , wherein the molar ratio of the compound of Formula (Ia) to tertiary-butylMgX 1 is from about 1:1 to about 1:5; step (a) is conducted at a temperature of from about 15° C. to about 100° C. and in the presence of a solvent system comprising an aprotic solvent; the reaction of step (b) is cooled to a temperature of less than 20° C.; and step (d) is repeated up to four times.

14. The process of claim 13 , wherein X 1 is chloride or bromide, and the solvent system comprises toluene and tetrahydrofuran.

15. The process of claim 11 , wherein an amount of the compound of Formula (IIa) crystallizes in step (b) as the reaction product is cooled.

16. The process of claim 15 , wherein the crystallization temperature is from about 15° C. to about 60° C. the first time step (b) is performed.

17. The process of claim 15 , wherein the crystallization temperature is from about 25° C. to about 55° C. the fourth time step (b) is performed.

18. The process of claim 11 , wherein the yield of the compound of Formula (IIa) is greater than about 70%, based on the amount of the compound of Formula (Ia) mixed with R 9 MgX 1 in step (a).

19. The process of claim 11 , wherein repeating step (d) four times increases the yield of the compound of Formula (IIa) by at least 20% compared to when no recycling step (d) is performed.

20. The process of claim 11 , wherein the optical activity of the compound of Formula (Ia) or (IIa) is selected from the group consisting of (+), (−), the configuration of each of C5 and C6 is R; and the configuration of C7, C9, C13, and C14, respectively, is selected from the group consisting of RRSS, RSRR, SRSS, and SSRR, provided that the C15 and the C16 carbons are both either on the alpha face or the beta face of the molecule.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2009
From: KALOTA, DENNIS J.
To: MALLINCKRODT INC.
Reel/Frame 023395/0872 →
Continuity (2)
Provisional Application 61194697 · Sep 30, 2008
Related Publication 20100081815A1 · Apr 1, 2010